Incidence and Relapse of Idiopathic Nephrotic Syndrome: Meta-analysis - PubMed (original) (raw)
Meta-Analysis
. 2021 Jul;148(1):e2020029249.
doi: 10.1542/peds.2020-029249. Epub 2021 Jun 30.
Affiliations
- PMID: 34193618
- DOI: 10.1542/peds.2020-029249
Meta-Analysis
Incidence and Relapse of Idiopathic Nephrotic Syndrome: Meta-analysis
Floor Veltkamp et al. Pediatrics. 2021 Jul.
Abstract
Context: Idiopathic nephrotic syndrome (INS) in children is a disease with considerable morbidity, yet the incidence and risk for relapse have not been systematically reviewed.
Objective: To estimate the overall pooled weighted incidence and risk for relapse of INS in children.
Data sources: Medline and Embase (until December 2020).
Study selection: All studies reporting incidence (per 100 000 children per year) and/or risk for relapse (the proportion of patients who experience ≥1 relapse) of INS in children (age: <18 years) were eligible.
Data extraction: After quality assessment, data were extracted: study (design, localization, and sample size) and patient (age, sex, steroid response, and ethnicity) characteristics, incidence, and risk for relapse.
Results: After screening, 73 studies were included for analysis (27 incidence, 54 relapse). The overall pooled weighted estimate and corresponding prediction interval (PI) of the incidence was 2.92 (95% PI: 0.00-6.51) per 100 000 children per year. Higher incidences were found in non-Western countries (P < .001). Incidence tended to be lower in white children, but this was not significant. The overall pooled weighted estimate of the risk for relapse was 71.9% (95% PI: 38.8-95.5). Between 1945 and 2011, incidence did not change (P = .39), yet the risk for relapse decreased significantly (P = .024), from 87.4% to 66.2%.
Limitations: There was no full-text availability (n = 33), considerable heterogeneity, and limited studies from Africa, Latin America, and Asia.
Conclusions: INS has a low incidence with ethnic variation but high risk for relapse. Although corticosteroids have significantly reduced the risk for relapse, it remains unacceptably high, underscoring the need for alternative treatment strategies.
Copyright © 2021 by the American Academy of Pediatrics.
Conflict of interest statement
POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.
Similar articles
- High incidence of idiopathic nephrotic syndrome in East Asian children: a nationwide survey in Japan (JP-SHINE study).
Kikunaga K, Ishikura K, Terano C, Sato M, Komaki F, Hamasaki Y, Sasaki S, Iijima K, Yoshikawa N, Nakanishi K, Nakazato H, Matsuyama T, Ando T, Ito S, Honda M; Japanese Pediatric Survey Holding Information of NEphrotic syndrome (JP-SHINE) study of the Japanese Study Group of Renal Disease in Children. Kikunaga K, et al. Clin Exp Nephrol. 2017 Aug;21(4):651-657. doi: 10.1007/s10157-016-1319-z. Epub 2016 Sep 2. Clin Exp Nephrol. 2017. PMID: 27590892 - Long-term outcomes in idiopathic nephrotic syndrome: from childhood to adulthood.
Skrzypczyk P, Panczyk-Tomaszewska M, Roszkowska-Blaim M, Wawer Z, Bienias B, Zajgzkowska M, Kilis-Pstrusinska K, Jakubowska A, Szczepaniak M, Pawlak-Bratkowska M, Tkaczyk M. Skrzypczyk P, et al. Clin Nephrol. 2014 Mar;81(3):166-73. doi: 10.5414/CN108044. Clin Nephrol. 2014. PMID: 24361057 - Prediction of Risk Factors of Frequent Relapse Idiopathic Nephrotic Syndrome.
Jahan I, Hanif M, Ali MA, Hoque MM. Jahan I, et al. Mymensingh Med J. 2015 Oct;24(4):735-42. Mymensingh Med J. 2015. PMID: 26620012 - Corticosteroid therapy for nephrotic syndrome in children.
Hodson EM, Knight JF, Willis NS, Craig JC. Hodson EM, et al. Cochrane Database Syst Rev. 2001;(2):CD001533. doi: 10.1002/14651858.CD001533. Cochrane Database Syst Rev. 2001. PMID: 11405997 Updated. Review. - Corticosteroid therapy for nephrotic syndrome in children.
Hodson EM, Knight JF, Willis NS, Craig JC. Hodson EM, et al. Cochrane Database Syst Rev. 2004;(2):CD001533. doi: 10.1002/14651858.CD001533.pub2. Cochrane Database Syst Rev. 2004. PMID: 15106158 Updated. Review.
Cited by
- Exploring the therapeutic mechanism of Yuebi decoction on nephrotic syndrome based on network pharmacology and experimental study.
Yao T, Wang Q, Han S, Xu Y, Chen M, Wang Y. Yao T, et al. Aging (Albany NY). 2024 Sep 20;16(18):12623-12650. doi: 10.18632/aging.206116. Epub 2024 Sep 20. Aging (Albany NY). 2024. PMID: 39311772 Free PMC article. - Corticosteroid therapy for nephrotic syndrome in children.
Hahn D, Samuel SM, Willis NS, Craig JC, Hodson EM. Hahn D, et al. Cochrane Database Syst Rev. 2024 Aug 22;8(8):CD001533. doi: 10.1002/14651858.CD001533.pub7. Cochrane Database Syst Rev. 2024. PMID: 39171624 Review. - Comparison of different genetic testing modalities applied in paediatric patients with steroid-resistant nephrotic syndrome.
Cheng X, Chen J, Yang X, Chan H, Yang X, Jiao J, Wang A, Zhang G, Chen X, Li X, Wang M, Yang B, Yang H, Li Q. Cheng X, et al. Ital J Pediatr. 2024 Apr 23;50(1):85. doi: 10.1186/s13052-024-01655-4. Ital J Pediatr. 2024. PMID: 38654395 Free PMC article. - Impact of childhood nephrotic syndrome on obesity and growth: a prospective cohort study.
Robinson CH, Aman N, Banh T, Brooke J, Chanchlani R, Dhillon V, Langlois V, Levin L, Licht C, McKay A, Noone D, Parikh A, Pearl R, Radhakrishnan S, Rowley V, Teoh CW, Vasilevska-Ristovska J, Parekh RS. Robinson CH, et al. Pediatr Nephrol. 2024 Sep;39(9):2667-2677. doi: 10.1007/s00467-024-06370-0. Epub 2024 Apr 18. Pediatr Nephrol. 2024. PMID: 38637343 - Mycophenolate Mofetil Versus Prednisone for Induction Therapy in Steroid-Sensitive Idiopathic Nephrotic Syndrome in Children: An Observational Study.
Mazo A, Kilduff S, Pereira T, Solomon S, Matloff R, Zolotnitskaya A, Samsonov D. Mazo A, et al. Kidney Med. 2023 Dec 10;6(3):100776. doi: 10.1016/j.xkme.2023.100776. eCollection 2024 Mar. Kidney Med. 2023. PMID: 38435073 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous